Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA101 nebulized therapy versus placebo and oral cromolyn in symptomatic indolent systemic mastocytosis
2014-004113-85Phase 2Completed
- Sponsor
- Patara Pharma
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in indolent systemic mastocytosis (ISM) comparing Randomized crossover: PA101/placebo with Open-label oral cromolyn sodium control (2 arms). Primary endpoint: Change from baseline in total symptom score. Started Dec 2014; status: completed.
02
Drugs
RVT-1601
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on 2014-004113-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004113-85.